NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal

Van K. Morris, Kristen K. Ciombor, Lianchun Xiao, Joshua K. Ochieng, Enrica Marmonti, Blase Polite, Benjamin A. Weinberg, John C. Krauss, John Hays, Sarbajit Mukherjee, Olivia Aranha, Syma Iqbal, Tony Shields, Al B. Benson, Syed Kazmi, Christopher Lieu, Howard Hochster, Jennifer Whisenant, Cara Haymaker, Cathy Eng

Open source

DOI: 10.1200/jco-25-00929
Published: 2026-02-20
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00929,
  title = {NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal},
  author = {Van K. Morris and Kristen K. Ciombor and Lianchun Xiao and Joshua K. Ochieng and Enrica Marmonti and Blase Polite and Benjamin A. Weinberg and John C. Krauss and John Hays and Sarbajit Mukherjee and Olivia Aranha and Syma Iqbal and Tony Shields and Al B. Benson and Syed Kazmi and Christopher Lieu and Howard Hochster and Jennifer Whisenant and Cara Haymaker and Cathy Eng},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-00929},
  url = {https://doi.org/10.1200/jco-25-00929}
}

RIS

TY  - JOUR
TI  - NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
AU  - Van K. Morris
AU  - Kristen K. Ciombor
AU  - Lianchun Xiao
AU  - Joshua K. Ochieng
AU  - Enrica Marmonti
AU  - Blase Polite
AU  - Benjamin A. Weinberg
AU  - John C. Krauss
AU  - John Hays
AU  - Sarbajit Mukherjee
AU  - Olivia Aranha
AU  - Syma Iqbal
AU  - Tony Shields
AU  - Al B. Benson
AU  - Syed Kazmi
AU  - Christopher Lieu
AU  - Howard Hochster
AU  - Jennifer Whisenant
AU  - Cara Haymaker
AU  - Cathy Eng
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-00929
UR  - https://doi.org/10.1200/jco-25-00929
ER  -

APA

Morris, V. K., Ciombor, K. K., Xiao, L., Ochieng, J. K., Marmonti, E., Polite, B., Weinberg, B. A., Krauss, J. C., Hays, J., Mukherjee, S., Aranha, O., Iqbal, S., Shields, T., Benson, A. B., Kazmi, S., Lieu, C., Hochster, H., Whisenant, J., Haymaker, C., & Eng, C. (2026). NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00929

Source records

crossref · retrieved 2026-09-27T08:51:03.745Z